Dr Cornelis van Tilburg speaks to ecancer about the clinical outcome and benefit for molecular subgroups seen in the paediatric precision oncology study INFORM.

He explains that INFORM is a non-interventional registry study that provided comprehensive molecular diagnostics and also clinical follow up allowing insight into treatments that benefit in certain alterations.

Dr van Tilburg reports that the study found that patients labelled with 'high level priority' alterations greatly benefited when treated with targeted drugs.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

свернуть